Study of Fluoxetine in Autism - Full Text View

Sponsors and Collaborators:	Neuropharm Autism Speaks
Information provided by:	Neuropharm
ClinicalTrials.gov Identifier:	NCT00515320

Purpose

The purpose of this study is to assess the effect of fluoxetine orally dissolving tablets (ODT) on the repetitive behaviors core domain in children and adolescents with Autistic Disorder. The study will also investigate the effect of fluoxetine on the improvement of symptoms and the effects on daily living of the patient's family.

Condition	Intervention	Phase
Autistic Disorder	Drug: Fluoxetine Drug: Placebo	Phase III

MedlinePlus related topics: Autism

Drug Information available for: Fluoxetine Serotonin Fluoxetine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.

Further study details as provided by Neuropharm:

Primary Outcome Measures:

The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score. [ Time Frame: Throughout the study ]

Secondary Outcome Measures:

The time and dose related course of therapeutic effects [ Time Frame: Throughout the study ]
The inter-relationship between these effects in the context of global clinical changes. [ Time Frame: Throughout the study ]
The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment. [ Time Frame: Throughout the study ]
Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests. [ Time Frame: Throughout the study ]

Estimated Enrollment:	128
Study Start Date:	August 2007
Estimated Study Completion Date:	January 2009
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Fluoxetine: Experimental	Drug: Fluoxetine
Placebo: Placebo Comparator	Drug: Placebo

Eligibility

Ages Eligible for Study:	5 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meets DSM-IV criteria for autistic disorder, .
CYBOCS-PDD score of at least 10 at screening.

Exclusion Criteria:

Diagnosis of Asperger Syndrome or Pervasive Developmental Disorder Not Otherwise Specified, Rett Syndrome, Childhood Disintegrative Disorder.
Patients planning to commence cognitive behaviour therapy during the period of the study or those who have begun cognitive behaviour therapy within 8 weeks prior to enrolment.
Patients who are currently taking fluoxetine or who have previously taken it are not eligible for the study.

Other protocol-defined Inclusion/Exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00515320

Locations

United States, Arizona
Southwest Autism Research and Resource Centre
Phoenix, Arizona, United States, 85006
United States, California
University of California Davis
Sacramento, California, United States, 95817
United States, Florida
University of Florida, Department of Psychiatry
Gainesville, Florida, United States, 32611
United States, Georgia
Institute for Behavioral Medicine
Smyrna, Georgia, United States, 30080
United States, Illinois
University of Illinois
Chicago, Illinois, United States, 60637-1448
AMR-Baber Research Inc.
Naperville, Illinois, United States, 60563
United States, Massachusetts
Harvard Medical School
Medford, Massachusetts, United States, 02155
United States, Michigan
Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
United States, Nevada
Center for Psychiatry and Behavioral Medicine
Las Vegas, Nevada, United States, 89128
United States, New Jersey
CRCNJ
Voorhees, New Jersey, United States, 08043
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Long Island Jewish Hospital
Bethpage, New York, United States, 11714
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic
Pittsburgh, Pennsylvania, United States, 15203
United States, Texas
Red Oak Psychiatry Associates
Houston, Texas, United States, 77090
United States, Washington
Seattle Children's Hosptial University of Washington
Seattle, Washington, United States, 98105-0371

Sponsors and Collaborators

Neuropharm

Autism Speaks

More Information

www.cureautismnow.org This link exits the ClinicalTrials.gov site

www.autismspeaks.org This link exits the ClinicalTrials.gov site

www.neuropharm.co.uk This link exits the ClinicalTrials.gov site

Responsible Party:	Neuropharm ( Dr Michael Snape / Chief Scientific Officer )
Study ID Numbers:	NPL-2008-4-AUTUS-004
Study First Received:	August 10, 2007
Last Updated:	September 11, 2008
ClinicalTrials.gov Identifier:	NCT00515320
Health Authority:	United States: Food and Drug Administration

Keywords provided by Neuropharm:

Autism
children
adolescent
Fluoxetine

Autistic Disorder
Repetitive behavior
SSRI
Selective Serotonin Reuptake Inhibitor

Study placed in the following topic categories:

Fluoxetine
Developmental Disabilities
Child Development Disorders, Pervasive
Mental Disorders

Autistic Disorder
Mental Disorders Diagnosed in Childhood
Serotonin

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors

Pharmacologic Actions
Pathologic Processes
Serotonin Agents
Therapeutic Uses
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 16, 2009